Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | FBP1 | P09467 | 7/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421412 | 0.83 | KDM4E (0.50) | PPARAPPARGCYP1A2CYP3A4TSHR | |
| SCHEMBL3484032 | 0.82 | PPARA (0.57) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL417160 | 0.80 | CNR2 (0.46) | PPARGCNR1 | |
| SCHEMBL3484509 | 0.78 | PPARA (0.56) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL4029401 | 0.78 | GRM2 (0.55) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL197882 | 0.77 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL20730087 | 0.77 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL12670824 | 0.76 | PPARA (0.62) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL14291406 | 0.76 | PPARA (0.69) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL421202 | 0.75 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| CN-102378753-A | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO LTD | 2012-03-14 | — | — | CN | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | PPARA 2465/4885PPARG 2361/4885FBP1 199/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | PPARA 2465/4885PPARG 2361/4885FBP1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.